OBJECTIVES: Percutaneous edge-to-edge devices for non-surgical repair of mitral valve regurgitation are under clinical evaluation in highrisk patients deemed not suitable for conventional surgery. To address guidelines for initial therapy decision, we here report on 13 cases of surgery after failed percutaneous edge-to-edge mitral valve repair or attempted repair, and discuss methodology and prognostic factors for operative outcome in this high-risk situation.
INTRODUCTION
Percutaneous mitral valve repair using the MitraClip (Abbott Vascular, Santa Clara, CA, USA) device has demonstrated similar effectivity in improving clinical outcome compared with conventional surgery. There are indications of a safer procedural profile in selected patients with severe mitral insufficiency and heart failure when compared with conventional surgery [1] [2] [3] . The results of conventional surgery, in specific, mitral valve repair for the treatment of mitral valve regurgitation are good both in younger and the elderly population [4, 5] . This indisputable fact hence sets a high standard for interventional mitral valve therapies. Mitral valve regurgitation represents 30% of native valve diseases, and the incidence is expected to rise with the overall ageing population. Percutaneous techniques for treatment of valvular diseases have experienced a huge lip forward during the last decade. These techniques are largely viewed as useful armamentarium for patients who would have gone untreated. However, long-term results of patients treated especially with the novel MitraClip device are lacking [6, 7] . Various factors may determine who best suits for this therapy and these factors include pathology of mitral valve disease. The purpose of this report is to present our experience with high-risk patients evaluated for and treated with the MitraClip device who, however, subsequently underwent salvage mitral valve surgery. We believe that analysis of complications would contribute immensely to future practice of MitraClip interventions.
PATIENTS AND METHODS

Methods
All procedures including indications for treatment of mitral regurgitation in 139 patients by means of MitraClip technique has been previously described by Paranskaya et al. [8, 9] . Patients discharged from hospital were followed up regularly at discharge, 1-month, 3-month, 6-month and yearly intervals. A follow-up evaluation after index MitraClip procedure focused primarily on data concerning cardiac failure rehospitalizations, reinterventions ( percutaneously or surgically) and death. We identified 13 patients suitable for our analysis. Patients with progredient symptoms were evaluated clinically and echocardiographically. Those with recurrent mitral regurgitation or mitral valve stenosis were evaluated for underlying pathomechanism of MitraClip failure, at first echocardiographically and intrasurgical when conventional surgery was feasible. All surgical procedures in patients requiring mitral valve surgery after MitraClip therapy were performed either in a hybrid operating theatre in cases of emergency surgery or in theatre if patients were electively referred for surgery.
Patients
Of 455 mitral valve surgeries performed between January 2010 and February 2013, 139 (31%) were carried out percutaneously with the MitraClip device in patients presenting with severe mitral regurgitation, after prohibitive surgical risks were assessed by a heart team consensus. Of the 139 patients receiving the MitraClip device, 13 (9%) subsequently underwent conventional heart surgery amounting to 3% of the overall mitral valve surgeries. Thirteen patients scheduled for heart surgery after MitraClip therapy received valve replacement with various concomitant procedures. Time interval between MitraClip placement and necessity for conventional surgery ranged between 0 (n = 2, emergency surgical salvage) and 409 days with 12 (92%) patients presenting ≤365 days post index procedure. Clinical follow-up post-conventional surgery was available in all patients (100%). Tables 1 and 2 present patients baseline characteristics and aetiology of mitral regurgitation of all 13 patients requiring conventional surgery after MitraClip therapy.
RESULTS
Indications for mitral valve surgery post MitraClip therapy and intraoperative findings
Thirteen of 139 (9%) patients treated with the MitraClip device were subsequently referred for conventional surgery at intervals ranging from 0 and 409 days, respectively. Eleven (85%) of the 13 patients referred for reoperative surgery after MitraClip therapy presented within 1 year of index procedure. Indications for reoperative surgery were persistent mitral regurgitation greater than grade 2 in 2 patients, recurrent mitral regurgitation greater than grade 2 in 8 patients, mitral stenosis greater than grade 2 in 3 patients. Preoperative echocardiography and intrasurgical direct visualization revealed different pathomechanisms of MitraClip failure warranting surgery. Patients 1 and 13 were transferred from the hybrid suite to surgical theatre immediately after MitraClip intervention for emergent mitral valve surgery due to clip embolization, and complete MitraClip detachment from the anterior mitral leaflet resulting in grade 4 mitral regurgitation. In patients 3, 4 and 11, placement of 3, 2 and 4 MitraClip devices resulted in mitral stenosis at 7, 365 and 27 days post MitraClip, respectively. See Table 3 for details.
Since most of the patients presented with concomitant cardiac pathologies calling for surgical attention, we opted for less time consuming surgical options for all patients. Mitral valve replacement was performed in all 13 patients requiring mitral valve surgeries. Details of surgery, intraoperative findings and concomitant procedures are shown in Table 4 .
To our utmost surprise, there was one case of subacute bacterial endocarditis (endocarditis ulceropolyposa) in 1 patient (Patient 9), unfortunately during autopsy. Strikingly, this diagnosis went undetected clinically and echocardiographically prior to surgery. Endocarditis in human post MitraClip therapy, to the best of our knowledge, has not been reported before. The diagnosis of infective endocarditis in patients treated with the MitraClip device may probably be very challenging. As with other prosthetic devices, infective endocarditis probably remains a potential complication [8] .
Acute outcomes
Surgical success was achieved in all 13 patients. We opted for mitral valve replacement surgery in all 13 patients with various concomitant procedures (see Table 4 ). One patient died on the second postoperative day due to intractable right heart failure making up a 30-day mortality of 8%. At follow-up interval ranging between 4 and 28 months, of the 12 (93%) patients who were discharged out of hospital to rehabilitation settlements in whom follow-up was available, all patients were alive and no residual mitral regurgitation was documented at a mean follow-up duration of 10 ± 7 months. Overall survival ranged between 8 and 39 months, with 2 patients dying at 8 and 21 months of undisclosed causes of death post-surgery. No residual mitral regurgitation was documented at a mean follow-up duration of 17 ± 10 months.
In-hospital course and follow-up
All patients were transferred successfully from the operating room to the intensive care unit. Twelve patients required inotropic support for a mean duration of 40 ± 39 h. Mean duration of mechanical ventilation was 44 ± 40 and mean ICU stay was 6 ± 8 days.
Mean in-hospital stay was 20 ± 7 days. One patient died 20 h after mitral valve surgery due to fulminant right heart failure. He presented with a logistic EuroSCORE of 27 and pro-BNP value of 7000 pg/ml. Indications for surgery were mitral regurgitation and tricuspid regurgitation grade III°, respectively, and ischaemic heart disease, having previously underwent coronary artery intervention with stent grafts placement. All other patients were discharged to rehabilitation homes at intervals ranging between 7 and 28 days. Table 5 further illustrates details of in-hospital course.
Follow-up was complete in all patients at various intervals postsurgery. Table 6 illustrates details of last follow-up of all patients. Third clip embolized into the renal artery with no sequelae at follow-up.
ADULT CARDIAC
A. Alozie et al. / European Journal of Cardio-Thoracic Surgery
Two patients died during the follow-up period of undisclosed causes. The remaining patients were alive at the time of follow-up, and no recurrent mitral regurgitation was recorded on echocardiography. Quality of life improved compared with their various preoperative status.
DISCUSSION
The percutaneous edge-to-edge device for non-surgical repair of mitral valve regurgitation is under clinical evaluation in high-risk patients deemed not suitable for conventional surgery. To address guidelines for initial therapy decision, we here report on 13 cases of surgery after failed percutaneous edge-to-edge mitral valve repair or attempted repair, and discuss methodology and prognostic factors for operative outcome in this high-risk situation.
In our series, 3 patients receiving ≥2 MitraClip devices presented at 7, 27 and 365 days, respectively, post index procedure with significant mitral valve stenosis warranting surgical interventions. The healing response of the MitraClip device in humans is temporarily not well known. We hypothesize that inflammatory reactions, fibrosis occurring around the leaflets after MitraClip procedures in certain patients with peculiar predisposition, may lead to overwhelming healing process paving the way for stenotic mitral physiology. Currently, there is no evidence to support this, and hence this assumption has to be proven in future studies. Progressive dystrophic calcifications, a hallmark of prosthesis degeneration in patients with high calcium load, especially those with uraemia, should be considered when planning for MitraClip interventions. In this context, Pope et al. [10] reported a late calcific mitral stenosis in a dialysis dependent patient 28 months after MitraClip therapy for functional mitral regurgitation. Two MitraClip devices were initially placed successfully in the described patient. Recently, Cockburn et al. [11] presented the case of a 74-year old patient treated with one MitraClip device presenting 3 months post MitraClip procedure with severe mitral valve stenosis. Coincidentally, 3 of our patients who subsequently underwent conventional reoperative mitral valve surgery were all treated with ≥2 MitraClip devices. Though the intervals of 7 and 27 days in the first 2 patients do not allow for speculations on impact of pathological healing process, but the third patient with 365 days interval does allow for this type of speculation. Patients with justifiable operative risk, when foreseeable that multiple clip devices would be required to achieve acceptable results, should be treated with [12, 13] . Our findings with reoperative surgery after percutaneous MitraClip therapy are in accordance with the results of the long awaited 4-year durability results of patients treated with the MitraClip device vs conventional surgery within the Everest II clinical trial. In the intention-to-treat analysis, surgery for mitral valve dysfunction occurred at the rate of 20.4 vs 2.2% (P < 0.001) and 24.8 vs 5.5% (P < 0.001) at 1-and 4-year intervals, respectively. Most surgical revisions after the MitraClip therapy occurred within 1 year of the index procedure [14] . On the other hand, rates of 30-day adverse events were higher in the surgical group compared with the MitraClip therapy group; however, considering the risks associated with reoperative mitral valve surgery after primary MitraClip intervention, these results may be offset by the low residual regurgitation requiring repeat mitral valve surgery in patients treated by means of conventional surgery. Moreover, there were no significant differences in mortality in both groups at the end of 1 and 4 years, respectively. Patients treated with the MitraClip device should be monitored close meshed within the first year of the index procedure. Requirement for reinterventions with either the MitraClip device or the conventional surgery should be identified and treated as early as possible in eligible patients. Our results are in line with the few published series of surgery post MitraClip therapy [15] [16] [17] . The decision to replace or repair the mitral valve depends mostly on underlying pathogenesis of the mitral regurgitation and experience of the surgical team. There may be the tendency to repair as much valves as possible, even at the expense of extended surgical duration in some centres. Our patients presented mostly in poor clinical state and, hence, we resorted to valve replacement strategy as this in our opinion was the shortest possible treatment strategy. We obtained optimal results considering the fact that these patients were initially classified as high-risk patients in a heart team approach.
CONCLUSIONS
The advance of MitraClip therapy for mitral regurgitation depends on the understanding of mitral pathophysiology in every single patient. Potential benefits of the device and its limitations should be continuously evaluated in the future. Contrary to the results of the Everest II clinical trial, standard of care options were not preserved in most of our patients. MitraClip is a promising new strategy for treating patients considered too high-risk for conventional surgery. The establishment of further clinical and echocardiographybased selection criteria will help identify suitable patients for treatment with the MitraClip device and this assertion remains of utmost importance, as patient selection may affect long-term outcome and is in our opinion paramount to achieving less complications.
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